Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
NanoViricides president backs FDA's targeted COVID booster policy shift
09:24am, Thursday, 22'nd May 2025
NanoViricides (NYSE-A:NNVC) president Dr Anil Diwan has welcomed a new US Food and Drug Administration policy that limits broad COVID-19 vaccine booster recommendations, calling it a “rational and s
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
06:30am, Thursday, 22'nd May 2025
SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA.
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox
09:10am, Friday, 16'th May 2025
NanoViricides (NYSE-A:NNVC) is preparing a Phase II clinical trial application for its lead antiviral candidate NV-387 to treat Mpox infections in Central Africa, marking a major step in the company's
NanoViricides progresses antiviral portfolio as measles and MPox threats rise
09:09am, Wednesday, 14'th May 2025
NanoViricides Inc (NYSE American: NNVC) said on Wednesday it is moving forward with trials of its antiviral drug NV-387 to combat a growing number of viral threats, including measles and MPox, amid ri
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC
08:58am, Thursday, 08'th May 2025
NanoViricides (NYSE-A:NNVC) said on Thursday it has received ethics committee approval in the Democratic Republic of Congo to move forward with a planned Phase II clinical trial of its antiviral drug
SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES) of
NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
06:30am, Monday, 05'th May 2025
Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivira
NanoViricides advances measles drug development amid rising US cases
09:23am, Tuesday, 29'th Apr 2025
NanoViricides (NYSE-A:NNVC) said it is moving forward with the development of a drug to treat measles, as US health officials report a continuing rise in infections amid declining vaccination rates. T
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
06:30am, Tuesday, 29'th Apr 2025
SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum ant
NanoViricides evaluating antiviral drug NV-387 for measles treatment
08:59am, Monday, 14'th Apr 2025
NanoViricides (NYSE-A:NNVC) has begun evaluating its clinical-stage antiviral NV-387 for the treatment of measles, a disease with no currently approved drug treatment. “A drug for measles is at pres
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
06:30am, Monday, 14'th Apr 2025
SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum ant
NanoViricides unaffected by US tariff turmoil, says CFO
12:56pm, Saturday, 05'th Apr 2025
NanoViricides (NYSE-A:NNVC) chief financial officer Meeta Vyas talked with Proactive about the company's progress developing broad-spectrum antiviral therapeutics and how its technology remains unaffe
NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative
09:17am, Friday, 28'th Mar 2025
The US Department of Agriculture (USDA) will invest up to $100 million to combat highly pathogenic avian influenza (HPAI), funding research into prevention, therapeutics, and vaccine candidates, the a
NanoViricides says business unaffected by US tariffs, highlights antiviral pipeline
08:54am, Tuesday, 11'th Mar 2025
NanoViricides (NYSE-A:NNVC) said on Tuesday that its business remains unaffected by US government tariffs, retaliatory trade policies, or federal spending cuts. In a statement, the clinical-stage biot
SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that th
